eCite Digital Repository

Quality of life utility values for hereditary haemochromatosis in Australia


de Graaff, B and Neil, A and Sanderson, K and Yee, KC and Palmer, AJ, Quality of life utility values for hereditary haemochromatosis in Australia, Health and Quality of Life Outcomes, 14, (1) Article 31. ISSN 1477-7525 (2016) [Refereed Article]


Copyright Statement

Copyright 2016 de Graaff et al. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0)

DOI: doi:10.1186/s12955-016-0431-9


BACKGROUND: Hereditary hemochromatosis (HH) is a common autosomal recessive disorder amongst persons of northern European heritage. If untreated, iron accumulates in parenchymal tissues causing morbidity and mortality. As diagnosis often follows irreversible organ damage, screening programs have been suggested to increase early diagnosis. A lack of economic evidence has been cited as a barrier to establishing such a program. Previous analyses used poorly estimated utility values. This study sought to measure utilities directly from people with HH in Australia.

METHODS: Volunteers with HH were recruited to complete a web-based survey. Utility was assessed using the Assessment of Quality of Life 4D (AQOL-4D) instrument. Severity of HH was graded into four categories. Multivariable regression analysis was performed to identify parameters associated with HSUV.

RESULTS: Between November 2013 and November 2014, 221 people completed the survey. Increasing severity of HH was negatively associated with utility. Mean (standard deviation) utilities were 0.76 (0.21), 0.81 (0.18), 0.60 (0.27), and 0.50 (0.27) for categories 1-4 HH respectively. Lower mean utility was found for symptomatic participants (categories 3 and 4) compared with asymptomatic participants (0.583 v. 0.796). Self-reported HH-related symptoms were negatively associated with HSUV (r = -0.685).

CONCLUSIONS: Symptomatic stages of HH and presence of multiple self-reported symptoms were associated with decreasing utility. Previous economic analyses have used higher utilities which likely resulted in underestimates of the cost effectiveness of HH interventions. The utilities reported in this paper are the most robust available, and will contribute to improving the validity of future economic models for HH.

Item Details

Item Type:Refereed Article
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Haematology
Objective Division:Health
Objective Group:Clinical health
Objective Field:Diagnosis of human diseases and conditions
UTAS Author:de Graaff, B (Dr Barbara de Graaff)
UTAS Author:Neil, A (Associate Professor Amanda Neil)
UTAS Author:Sanderson, K (Associate Professor Kristy Sanderson)
UTAS Author:Yee, KC (Dr Kwang Yee)
UTAS Author:Palmer, AJ (Professor Andrew Palmer)
ID Code:107821
Year Published:2016
Web of Science® Times Cited:10
Deposited By:Menzies Institute for Medical Research
Deposited On:2016-03-24
Last Modified:2017-11-03
Downloads:124 View Download Statistics

Repository Staff Only: item control page